Clinical Scorecard: Alterations in GLP-1 and GIP Levels Following Sleeve Gastrectomy and Subsequent Weight Regain in Adolescents: Is Additional Support Necessary?

At a Glance

Key Highlights

• LSG is the most common bariatric procedure in adolescents, producing significant and durable weight loss and metabolic improvements.
• Postoperative increases in GLP-1 and GIP contribute to weight loss and insulin sensitivity but may decline over time, correlating with weight regain.
• Weight regain typically occurs 2–3 years post-LSG and may be mitigated by adjunctive pharmacotherapy such as GLP-1 receptor agonists (e.g., semaglutide).

Guideline-Based Recommendations

Diagnosis

• Assess adolescent morbid obesity with BMI and metabolic comorbidities prior to LSG.
• Conduct comprehensive psychological evaluation to identify readiness and rule out eating disorders or mood disturbances.
• Measure GLP-1 and GIP levels pre- and postoperatively to monitor hormonal changes influencing weight outcomes.

Management

• Implement laparoscopic sleeve gastrectomy with antral resection (first staple firing 2 cm from pyloric ring) for adolescents with morbid obesity.
• Provide structured pre- and postoperative nutritional counseling with staged dietary progression.
• Offer behavioral support including psychological counseling, physical activity encouragement, and vitamin supplementation adherence.
• Consider adjunctive pharmacological therapy (e.g., semaglutide) to address weight regain occurring 2–3 years postoperatively.

Monitoring & Follow-up

• Schedule annual follow-up visits including anthropometric measurements, metabolic panels, and hormone assays (GLP-1, GIP).
• Use abdominal MRI to assess remnant gastric volume annually to detect anatomical changes related to weight regain.
• Monitor remission status of comorbidities (T2DM, hypertension, dyslipidemia) using established clinical criteria.

Risks

• Potential for weight regain due to declining incretin hormone responses and behavioral or anatomical adaptations.
• Psychological and developmental factors unique to adolescents may affect long-term adherence and outcomes.
• Need for ongoing multidisciplinary support to mitigate risk of relapse and ensure sustained weight loss.

Patient & Prescribing Data

Adolescents aged 10–19 years with morbid obesity undergoing LSG and experiencing weight regain

Semaglutide, a GLP-1 receptor agonist, may serve as an effective adjunct to counteract weight regain by enhancing incretin effects post-LSG.

Clinical Best Practices

• Ensure multidisciplinary preoperative assessment including psychological readiness and nutritional evaluation.
• Adopt standardized surgical technique with antral resection to optimize hormonal response.
• Maintain structured postoperative dietary progression and behavioral support to promote adherence.
• Implement long-term follow-up with annual clinical, metabolic, and hormonal assessments.
• Consider early pharmacological intervention with GLP-1 receptor agonists in cases of weight regain.

References

• Shehata et al. 2025 Seven-year follow-up study on LSG in adolescents
• American Diabetes Association (ADA) criteria for T2DM remission
• Pediatric hypertension guidelines
• National Lipid Association recommendations